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Nisoldipine, a calcium entry blocker, was given to 10
patients with congestive heart failure. During a 2 month
follow-up period, 7 of the 10 patients were readmitted
with pulmonary edema; daily furosemide doses were in-
creased (128 ± 87 to 192 ± 135mg/day, p < 0.01), and
plasma creatinine increased (1.5 ± 0.5 to 1.8 ± 0.6
mg/dl, p < 0.05) (all values mean ± SO). Despite this
unfavorable clinical course, nisoldipine caused some
beneficial chronic (1 month) hemodynamic effects. It
decreased systemic vascular resistance (from 1,781 ±
229 to 1,306 ± 345 dynes-scm:", p < 0.01), decreased
mean arterial pressure (from 88 ± 0 to 74 ± 4 mm Hg,
p < 0.001) and increased stroke volume index (from 27
± 6 to 33 ± 9 mllmin per mI , p < 0.02). Heart rate ,
pulmonary capillary wedge pressure and stroke work
index did not change.
However, nisoldipine's chronic renal and neurohu-
moral effects were not as favorable. These were assessed
during a 5 hour water load (15 ml/kg body weight of
Many patients suffer from congestive heart failure as a result
of coronary artery disease and myocardial infarction . Al-
though anginal symptoms often disappear after infarction ,
a significant number of patients continue to have both heart
failure and anginal symptoms. Because most vasodilators
used to treat congestive heart failure have little or no ben-
eficial antianginal effects ( I), invest igators (2- 19) have been
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5% dextrose in water) and compared with the effects of
a water load before therapy. Nisoldipine did not change
creatinine clearance or sodium excretion, but decreased
water excretion (from 58 ± 35 to 46 ± 40% of water
load in 5 hours). Over this 5 hour study, mean plasma
vasopressin was also higher with nisoldipine (1.9 ± 2.3
versus 2.7 ± 3.2 pg/ml, p < 0.05), but mean plasma
aldosterone was lower (67 ± 31 to 47 ± 27 mg/dl, p <
0.05). During the 5 hour water load, plasma renin ac-
tivity increased (from 3.3 ± 1.6 to 5.6 ± 3.9 ng/ml per
hour, p < 0.05) as did plasma norepinephrine (from 615
± 384 to 744 ± 494 pg/ml, p < 0.05) with nisoldipine,
whereas during the control water load, plasma renin
activity tended to decrease and the increase in plasma
norepinephrine was not as sustained.
It is concluded that by causing further neurohumoral
activation, nisoldipine may worsen the symptoms of
congestive heart failure.
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assessing the effects of calcium entry blockers in these pa-
tients . However, reports about the efficacy of these agents
in treating heart failure have been conflicting and few data
are available on their long-term hemodynamic, neurohu-
moral , renal and clinical effect s (2- 19). These data are
particularly important in view of the known reflex neuro-
humoral stimulation that can occur with these drugs (20,21)
and the potentially harmful effects of further neurohumoral
stimulation in patients with congestive heart failure (22-25).
In this study we examined the long-term hemod ynamic ,
neurohumoral, renal and clinical effect s of nisoldipine , a
calcium entry blocker with potent vasodilating effects but
only mild negative inotropic effect s (26-28), in patient s
with both angina and conge stive heart failure . We chose
nisoldipine because it is thought to be a more vasospecific
and less negative inotropic agent than nifedipine (28) . In an
attempt to better delineate any renal or neurohumoral effect s
of nisoldipine, we chose to study its renal and neurohumoral
effect s during a 15 mllkg water load . We found that, despite
having some beneficial hemodynamic effects, nisoldipine
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could cause clinical deterioration especially in patients with
more severe heart failure and more neurohumoral activation .
Methods
Study patients (Table 1). Ten men with chronic conges-
tive heart failure (New York Heart Association functional
class III or IV) were chosen for the study. Their mean age
was 62 ± 7 years. The cause of their heart failure was
ischemic in all cases and 9 of the 10 patients had NYHA
class III or IV angina. The 10th patient had only rare anginal
attacks (every I to 2 months) . Six patients had had selective
coronary arteriography before the study and were found to
have inoperable three vessel disease. All patients had had
at least one documented myocardial infarction. After giving
informed consent (this study was approved by the ethic s
committee of our institution), all patients were hospitalized
for at least I week before the study and fed a diet containing
2 g of sodium/day with fluid intake restricted to a maximum
of 1,500 to 1,800 mllday. Once the patients' condition was
considered optimally controlled with digoxin and diuretics ,
and when their weight varied less than 0.5 kg over 3 con-
secutive days, they were considered ready to enter the study
and were transferred to the coronary care unit of this insti-
tution. Administration of digoxin and diuretics was discon-
tinued for 24 hours before each water load procedure. Vaso-
dilators were discontinued at least 3 days before the study .
One patient received captopril, which was discontinued 6
days before the study, one received prazosin, one received
nifedipine and two patients received isosorbide dinitrate.
Five patients received no vasodilator before the study.
Water loads and hemodynamic measurements (Table
2). The evening before the study, a 7F triple lumen, f1ow-
directed, balloon-tipped thermodilution catheter (Edwards
Laboratories) was inserted transcutaneously through the right
internal jugular vein by the Seldinger technique and ad-
vanced to a pulmonary "wedge" position according to pres-
sure tracings . Pulmonary artery, right atrial and pulmonary
capillary wedge pressures were monitored by a Gould-Sta-
tham P231 Id transducer and recorded on an Electronics for
Medicine VR-6 photographic recorder. Cardiac output was
measured with the computerized thermodilution technique
by injecting 10 ml of iced 5% dextrose in water. Systemic
arterial blood pressure was obtained through an intraarterial
catheter. After an overnight fast, and immediately before
the water load, baseline hemodynamic, renal and neuro-
humoral measurements were obtained (day 0) . Thereafter,
a 15 ml/kg body weight water load consisting of 5% glucose
in water was administered intravenously over 40 to 75 min-
utes, and renal excretion was monitored over the next 5
hours as previously described (29) . Once the water load was
started, blood was drawn every hour for 5 hours through
the arterial line for measurements of electrolytes, osmolal-
ity, blood urea nitrogen, glucose, creatinine, protein and
albumin. Samples were also taken for measurements of plasma
arginine-vasopressin, plasma renin activity and plasma al-
dosterone. Plasma norepinephrine and epinephrine samples
were drawn only before and at hours I and 4 of the water
load. Urine was obtained by spontaneous voiding every
hour. The volume of each collected urine sample was re-
corded and the urine was analyzed for electrolytes, osmo-
lality , urea nitrogen and creatinine. Derived hemodynamic
values were calculated as previously described (I).
Intravenous furosemide was given immediately after the
5 hour water load study as considered necessary to maintain
urinary output to within 500 ml of intake. The patient's
usual daily dose of digoxin was also given . No furosemide
was given < 14 hours before the next day's hemodynamic
study.
Nisoldipine therapy: initial study. The day after the
water load, after an overnight fast , baseline hemodynamic
measurements were taken and nisoldipine, 10 mg, was given
orally. Hemodynamic measurements were then repeated
hourly for 5 hours . The acute study ended and the patients
were started on 10 mg of nisoldipine twice a day if one of
the following end points was reached: I) a decrease in mean
arterial pressure between 10 and 20 mm Hg , or 2) a decrease
in systolic arterial pressure to < 100 mm Hg. If one of these
end points was not reached, patients received a 20 mg dose
of nisoldipine orally, had hemodynamic measurements re-
peated hourly for 5 hours and were started on nisoldipine ,
20 mg twice a day. Three patients received nisoldipine, 10
mg twice a day , and seven patients received nisoldipine, 20
mg twice a day .
Protocol of long-term study of nisoldipine therapy,
Once the acute studies were completed, the patients were
transferred to a medical ward and their prestudy digoxin
and diuretic were added to their nisoldipine dosage regimen.
Diuretic dosage was then adjusted up or down according to
the patient 's clinical course . No patient had symptomatic
hypotension and none had a reduction in nisoldipine dosage.
Between studies, the mean daily furosemide dose require-
ments increased from 128 ± 87 to 164 ± 132 mg/day (p
< 0.05 ), but the mean daily triamterene (80 ± 92 to 80
± 92 mg/day) and potassium supplement (18.4 ± 13.6 to
18.4 ± 13.6 mEq/day) doses remained the same . Between
studies all patients were followed up in the same manner
by the same cardiologist. Five of the nine patients included
in the chronic study were readmitted with pulmonary edema
within 3 weeks of initial treatment with nisoldipine and
remained in the hospital in the period before the chronic
study. The other four patients were readmitted electively 4
weeks after the initial study and were maintained on a diet
of 2 g of sodium/day with fluid restricted to 1,500 to 1,800
mllday.
After 27 days ofnisoldipine therapy. 24 hours before the
long-term study, digoxin and diuretics were withheld and
the patient s were transferred to the coronary care unit where
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Table l. Baseline Hemodyn ami c , Neurohumoral and Renal Ch aracterist ics of the 10 Patients
Patient No.
2 3* 4 5* 6 7 8 9 lO*t
Age (yr) 71 69 58 47 61 64 67 59 68 60
Heart rate (beats/min) 66 80 44 72 68 80 85 94 102 76
A. Hemodynamic
Mean arterial pressure 85 110 80 101 98 87 89 88 9 1 96
(mm Hg)
Cardiac index 2.0 2.2 1.8 2.2 2.4 1.4 2. 1 2.3 1.4 2.8
(liters/min per m2)
Stroke work index (g-m 29 27 40 30 4 1 14 16 16 II 38
per m2)
Pulmonary capillary 16 37 10 28 13 27 43 38 30 21
wedge pressure (mm
Hg)
Systemic vascular 1,994 1,957 1,895 1,466 1,801 1,846 1,524 1,566 2,586 1,506
resistance
(dynes-s-cm- ')
B. Neurohormonal
Plasma norepinephrine 319 644 97 249 303 870 423 98 1 75 1 667
(pg/rnl)
Plasma vasopressin < 0.5 6.6 < 0.5 < 0.5 1.1 8.0 2.0 < 0.5 7.8 0.6
(pg/rnl)
Plasma renin activity 8.4 1.8 1.5 8.6 2.3 4.3 6.5 3.0 7.9 1.5
(ng/rnl per h)
Plasma aldosterone 112 63 17 76 47 93 60 70 178 29
(ng/dl)
C. Renal
Creatinine clearance 31 53 86 113 69 46 63 40 59 88
(ml/min per 1.73 rrr')
Blood urea nitrogen 58 30 15 14 20 29 19 21 32 10
(rng/dl)
Urinary sodium 9.7 6.5 18.6 1.2 7.7 3.5 7.6 5.3 0.6 9.6
excreted (mEq/5
hours)
Water excretion % of 73 42 115 93 83 17 38 45 13 89
load (in 5 hours)
Plasma sodium 137 135 141 136 139 133 135 137 135 140
(rnfiqzfiter)
D. Furosemide (rng/day)
2 Months prestudy 160 80 20 160 80 320 120 160 160 20
First month of therapy 240 120 20 160 80 480 160 200 160 20
Second month of 240 160 20 240 80 Off Rx 240 240 200 20
therapy
E. Admissions for Pulmonary Edema
2 Months prestudy 0 0 0 I 0 0 0 0 0 0
First month of therapy I I 0 0 0 I I 0 I 0
Second month of 0 0 0 I 0 Off Rx 2 2 0 0
therapy
*Patients who had no increase in heart failure symptoms with nisoldipine; t remains on nisoldipine therapy but refused long-term invasive testing.
Off Rx = nisoldipine discontinued.
a 7F triple lumen flow-directed , balloon-tipped thermodi- w ithout interruption to properly assess the chronic effects
lution catheter and an arterial line were inserted percuta- of this drug. After an overnight fast, baseline measurements
neously . Their regular dose of nisoldipine was continued representing the trough effects of their regular twice daily
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Table 2. Summary of Water Load Protocols and Hemodynamic Measurements
Day 0
Control water load with
hemodynamic ,
neurohumoral and
renal measurements
Day I
Acute hemodynamic effects of
10 or 20 mg of nisoldipine,
or both
Day 28
Second water load on nisoldipine
with hemodynamic,
neurohumoral and renal
measurements
Day 29
Chronic hemodynamic effects of
10 or 20 mg of nisoldipine
dose of nisoldipine were taken, their regular dose of nisol-
dipine was given and a 15 mllkg water load procedure was
repeated (day 28). The patients' regular evening dose of
nisoldipine was also given to prevent interruption of this
drug's dosage regimen, Intravenous furosemide was given
immediately after the 5 hour water load study as necessary
to maintain urinary output within 500 ml of intake, No
furosemide was given < 14 hours before the next day's
hemodynamic study, The next morning, after an overnight
fast, baseline hemodynamic measurements were taken, the
regular dose of nisoldipine was given, and hemodynamic
measurements were repeated hourly for 5 hours (day 29).
Neurohumoral assays. Plasma levels of arginine va-
sopressin, renin activity, aldosterone, and epinephrine and
norepinephrine were measured according to methods pre-
viously developed and reported from our laboratory (29),
The mean normal plasma values in our laboratory are: nor-
epinephrine 170 ± 40 pg/ml, epinephrine 35 ± 8 pg/ml,
renin activity <2.5 ng/mllh for diets normal in sodium and
aldosterone $25 mg/dl for diets normal in sodium. Normal
values for plasma vasopressin were 0.5 to 2.5 pg/ml for
plasma sodium between 135 and 145 mEq/liter.
Other analytic procedures and calculations. Plasma
and urine osmolality was determined in duplicate on 250 ILl
samples by freezing-point depression (Advanced Instrument
Osmometer 3DII; Advanced Instruments, Inc.). Sensitivity
of the instrument is ± I mosmol and its coefficient of vari-
ation at 290 mosmol is 0.51%. Plasma for osmometry was
always collected on heparin and published recommendations
were strictly followed (30).
Patient follow-up. Patients were seen, questioned and
examined weekly between the acute and chronic study and
every 2 weeks for the next month. Their diuretic dose was
adjusted up or down depending on their clinical situation
and to permit them to maintain their regular daily activities.
Clinical deterioration of a patient's heart failure was con-
sidered to have occurred when that patient required hospital
readmission for control of worsening congestive symptoms
(all seven patients readmitted for worsening heart failure
had at least one episode of acute pulmonary edema that
occurred in some cases after an increase in daily diuretic
dose).
Statistical analysis. The 12 hemodynamic measure-
ments for the acute administration of both the first dose of
nisoldipine and maintenance dose of nisoldipine (acute con-
tro\, 1,2,3,4 and 5 hours and chronic control, 1,2,3,4
and 5 hours) were compared by a two-factor repeated mea-
sures analysis of variance followed by a Student-Neuman-
Keuls test (31). We were careful to compare all hemody-
namic values during both acute and chronic studies with the
acute control values, because the chronic control values
represent the trough value of the patient's previous regular
nisoldipine dose, The hourly hemodynamic effects of an
acute dose of nisoldipine (I, 2, 3,4 and 5 hours after dose)
given to the patients after I month of continuous nisoldipine
therapy were also compared with the trough effect of the
previous chronic dose by a two-factor repeated measures
analysis of variance followed by a Student-Neuman-Keuls
test.
The hemodynamic and neurohumoral effects of nisoldi-
pine on the water load were evaluated by a two-factor re-
peated measures analysis of variance followed by a Student-
Neuman-Keuls test. The hemodynamic and neurohumoral
changes during each hour of both water loads were compared
by a two-tailed paired t test. Because renal variables such
as creatinine clearance, sodium and water excretion reflect
the total effect over the whole 5 hour study, the mean of
the hemodynamic and neurohumoral values (baseline, I, 2,
3,4 and 5) during the control and 1 month water loads were
also compared by a two-tailed paired t test. The hemody-
namic, neurohumoral and renal variables of the patient who
did not have the long-term invasive study were not consid-
ered in the statistical analysis. A probability value of less
than 0.05 was considered significant. All values are mean
± SO unless otherwise specified.
Results
Clinical effectsofnisoldipinetherapy (Table 1). Seven
of the 10 patients studied developed at least one episode of
pulmonary edema during the 2 months of the study, often
despite an increase in diuretic therapy, Daily furosemide
requirements increased (128 ± 87 to 192 ± 135 mg/day,
p < 0.01) and plasma creatinine increased (1.5 ± 0,5 to
1.8 ± 0.6 mg/dl, p < 0,01) over this period. Although
there were no complaints of postural hypotension, after 2
months of nisoldipine therapy, lying to standing (after 1
minute of standing) arterial pressure decreased from 118/73
to 110/65 mm Hg (mean 88 ± 10 to 79 ± 7 mm Hg, p <
0.001). Before nisoldipine therapy, mean lying to standing
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blood pressure had not decreased (93 ± 8 to 91 ± 8 mm
Hg, p = NS).
Attacksofunstable anginacomplicated episodes of wors-
ening heart failure in fi ve of the seven patients who de-
veloped pulmonary edema. These fi ve attacks of unstable
angina wereclearly preceded by worsening heartfailure and
resolved after a mean diuresis of 3 liters, suggesting that
worsening heart failure led to unstable angina and not vice
versa. The patients who eventually developed pulmonary
edema with nisoldipine had more severe heart failure than
did the threepatients whodid notdevelop pulmonary edema
(Cases 3, 5 and 10).
Acute hemodynamiceffects(Fig. 1). Themaximal dose
of nisoldipine used was 10 mg in three patients and 20 mg
in seven patients. Acutely, nisoldipine therapy decreased
mean arterial pressure for the full 5 hours of hemodynamic
monitoring. This decrease was accompanied by a decrease
in systemic vascular resistance and a slight transientincrease
in stroke volume index (27 ± 6 to 32 ± 9 mllbeat per rrr' ,
p < 0.05). There was no-change in heart rate, stroke work
index, right atrial pressure or pulmonary capillary wedge
pressure.
Chronichemodynamic effects (Fig. 1). When thechronic
control hemodynamic values (trough effect of nisoldipine
12hours afteradministration werecompared withthe short-
term control hemodynamic values (before any nisoldipine
therapy) the onlydifference was a decrease in mean arterial
pressureat chronic control, suggesting that the majorhemo-
dynamic effects of nisoldipine were significantly reduced
12 hours after administration.
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The acute administration of nisoldipine after J month of
continuous nisoldipine therapy caused essentially the same
hemodynamic effects as the acute administration of the first
dose of nisoldipine (Fig. I) . This was true whether the
hourly effects of the acute administration of a maintenance
dose of nisoldipine was compared with the acute control or
chronic (trough effect of a chronic dose) control values.
These findings suggest that no hemodynamic tachyphylaxis
to nisoldipine had occurred during the 4 week study. Neither
the acute nor the chronic hemodynamic effects in a patient
receiving nisoldipine were useful in predicting whether that
patient would eventually develop worsening heart failure,
although the patients who eventually developed worsening
heart failure tended to have a smaller increase in stroke
volume index, and continued to have a lower stroke volume
index despite nisoldipine therapy. After I, 2 and 3 hours
of nisoldipine therapy, their stroke volume index only in-
creased from 25 ± 3 to 29 ± 6, 27 ± 7 and 26 ± 8
ml/beat per rn", respectively, whereas in the other patients,
during the same time period, stroke volume index increased
from 34 ± 5 to 38 ± 7,46 ± 2 and 45 ± 6 mllbeat per
m2 , respectively. The change in pulmonary capillary wedge
pressure caused by nisoldipine was negligible in all patients.
Effects of the water load before nisoldipine therapy,
By the end of the I hour infusion, there had been no sig-
nificanthemodynamicchanges indicating that the water load
was well tolerated by these patients. Heart rate (77 ± 17
to 73 ± 15 beats/min), mean arterial pressure (92 ± 9 to
90 ± 12 mm Hg), cardiac index (2.0 ± 0.4 to 2.0 ± 0.3
liters/min per nr'), pulmonary capillary wedge pressure (27
± 12 to 25 ± 10 mm Hg), stroke work index (25 ± II
to 25 ± 9 g-m per rrr') and systemic vascular resistance
(1,846 ± 366 to 1,793 ± 389 dynes-s-cm 5) remained the
same.
Arterial norepinephrine did not increase by the end of
the l-hour water load but had increased by the end of the
study (Fig. 2). As in our previous water load studies (29),
in this study plasma renin and plasma aldosterone values
tended to decrease and plasma vasopressin decreased during
the water load (Fig. 2).
Effects of the water load during chronic nisoldipine
therapy. When pre-water load baseline values are com-
pared (precontrol water load versus prechronic nisoldipine
water load), there are some differences. Although plasma
norepinephrine and plasma vasopressin values tended to be
higher and plasma aldosterone tended to be lower during
the trough effect of nisoldipine therapy, the only significant
neurohumoral difference at this time was a lower plasma
renin activity (Fig. 2). Plasma sodium was also higher (138
± 2 versus J36 ± 2 mliq/liter, p < 0.05) and plasma
potassium was lower (4.5 ± 0.2 versus 5.0 ± 0.3 mliq/liter,
p < 0.05) before the chronic nisoldipine water load.
Nisoldipine caused significant changes in the neurohu-
moral response to the water load (Fig . 2). It caused a more
sustained increase in plasma norepinephrine and it caused
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Figure 2. Neurohumoral changes during a 5 hour water load be-
fore therapy (0 ) and during the short-term administration of a
chronic dose of nisoldipine (e) . With nisoldipine, the increase in
plasma norepinephrine was more sustained, mean plasma vaso-
pressin during the whole of the water load was increased . plasma
renin activity increased instead of tending to decrease and mean
plasma aldosteroneduring the whole of the water load decreased.
Values are mean z SE. + p < 0.05, + + P < 0.01 versus control
pre-water load values; * p < 0.05. ** P < 0.01 between hourly
values of the control and nisoldipine water loads.
plasma renin activity to increase. Also, although nisoldipine
did not prevent a decrease in plasma vasopressin in response
to the water load over the 5 hour period of the study, it did
cause mean plasma vasopressin to increase and water ex-
cretion to decrease (Fig. 2 and 3). Finally, urinary creatinine
clearance and sodium excretion did not change with nisol-
dipine, whereas mean plasma aldosterone decreased (Fig.
2 and 3).
The neurohumoral and renal effects of nisoldipine were
particularly marked in the seven patients who eventually
developed pulmonary edema. In these patients, plasma renin
activity nearly doubled during the water load with nisol-
dipine (3.43 ± 1.65 to 6.77 ± 3.63 ng/ml per h), plasma
norepinephrine increased to values more than 1,000 pg/ml in
four of these seven patients, mean plasma vasopressin in-
creased in six of the seven patients and water excretion
decreased to very low levels in all seven patients (46 ± 29
to 32 ± 30%).
Discussion
This study indicates that despite having some beneficial
hemodynamic effects, nisoldipine may increase neurohu-
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who eventually developed symptoms of worsening heart
failure, the increase in cardiac output with nisoldipine was
inadequate to compensate for the significant and sustained
decrease in mean arterial pressure that it caused, and thus
inadequate to prevent further neurohumoral stimulation and
sodium and water retention. Also, because we assessed the
neurohumoral effects of nisoldipine with patients in the su-
pine position and our patients had significant postural hy-
potension with nisoldipine, it is likely that our study under-
estimated the true neurohumoral stimulatory effects of
nisoldipine. Finally, because the effects of nisoldipine had
nearly totally dissipated by the end of a dose interval it is
possible that more frequent dosing may have led to more
sustained hemodynamic renal and neurohumoral changes.
As has been shown in previous studies (20-22), nisol-
dipine has, at most, only mild in vivo negative inotropic
effects, with cardiac index increasing and stroke work index
remaining the same. However, as proposed by Josephson
and Singh (16), it appears that the mild negative inotropic
effects of calcium entry blockers such as nisoldipine may
become important in patients in whom reflex neurohumoral
mechanisms are already largely activated and myocardial
reserve is nearly exhausted. It does not appear that their
deleterious effects are due to a decrease in cardiac index
because cardiac index increased, even in those patients who
eventually developed pulmonary edema, but rather because
they may prevent the increase in cardiac index from being
adequate enough to compensate for a significant decrease
in mean arterial pressure, and from further neurohumoral
stimulation and the detrimental effects that these cause
(21-25).
Renal and neurohumoral effects. Renal effects. The
decrease in water excretion and the increase in fluid retention
with nisoldipine were probably caused by the effect of ex-
trarenal factors, such as further neurohumoral stimulation,
on the kidney and not by the direct renal effects of nisol-
dipine, because: I) calcium entry blockers such as nisol-
dipine are not known to have direct deleterious renal effects
(12,14,33),2) creatinine clearance remained the same during
the water load with nisoldipine as compared with the control
water load, and 3) plasma creatinine remained unchanged
during the first month of therapy. For these same reasons,
the increase in plasma creatinine during the second month
of nisoldipine therapy was probably secondary to a further
increase in diuretic use and not to direct deleterious renal
effects of nisoldipine.
Increased plasma vasopressin. Plasma vasopressin in-
creased and water excretion decreased in six of the seven
patients who eventually required readmission for worsening
heart failure, suggesting a relation between increasing plasma
vasopressin and worsening heart failure. The increase in
plasma vasopressin between the control and long-term water
loads was at least partially attributable to the increase in
plasma sodium that occurred between the two studies. How-
ever, it may have also been partially attributable to a de-
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Figure 3. Chronic renal effects of nisoldipine. Nisoldipine did
not change creatinine clearance or blood urea nitrogen, but it did
decrease water excretion and increased daily furosemide require-
ments. Nisoldipine tended to increase bothurinary sodium excreted
and minimal urinary osmolality. Values are mean ±SE. * p <
0.05 chronic nisoldipine (solid bars) versus control (open bars).
moral stimulation and worsen the symptoms of congestive
heart failure.
Hemodynamic effects. The abnormal increase in sys-
temic vascular resistance of patients with congestive heart
failure is the result of compensatory neurohumoral mech-
anisms designed to increase cardiac output and to maintain
adequate perfusion pressure to essential organs (22-24).
Vasodilator therapy was introduced to normalize systemic
vascular resistance and increase cardiac output (20,25).
Whether the increase in cardiac output caused by these drugs
is sufficient to compensate for the neurostimulatory effects
of the decrease in mean arterial pressure that they cause
depends on the baseline status of a given patient and on the
vasodilator used (21,29). If the increase in cardiac output
is sufficient to compensate for the decrease in mean arterial
pressure, compensatory neurohumoral mechanisms are de-
creased and sodium and water excretion increases (29,32).
If the contrary is true, compensatory neurohumoral mech-
anisms are further increased and sodium and water retention
occurs (29,32). In this study, despite causing significant
vasodilation, nisoldipine caused only minor hemodynamic
improvements. It would appear that in the seven patients
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crease in myocardial contractility and to the decrease in
mean arterial pressure caused by nisoldipine (34-38). Why
a decrease in arterial pressurewith nisoldipine should cause
an increase in plasma vasopressin, whereas similar de-
creases in mean arterial pressure with prazosin or captopril
do not (29), remains speculative. However, there are two
important differences between nisoldipine and these two
vasodilators which may affect left ventricular volume or
other receptors(34-38) responsiblefor the nonosmotic stim-
ulation of plasma vasopressin in patients with congestive
heart failure: I) in vitro, nisoldipine has mild negative ino-
tropic effects that may become apparent in patients with
severe congestive heart failure whose myocardial reserve is
already exhausted, and 2) nisoldipine does not decrease
preload. In any case, the increase in plasma vasopressin
with nisoldipine led to decreased water excretion and prob-
ably contributed to the fluid retention and increased furo-
semide requirements of the seven patients with the most
severe heart failure.
Increased plasma sodium. Usually, in congestive heart
failure, hyponatremia reflects the severity of heart failure
and is the result of a convergence of a number of factors:
plasma vasopressin, intrarenal factors, activation of the renin-
angiotensinsystem, diet and diuretic use (32,38-42). Inour
study, plasma sodium paradoxically increased in the face
of increased diuretic requirements, increased plasma va-
sopressin, decreasedwaterexcretionand worsening conges-
tive symptoms of heart failure. There are no easy expla-
nations for these results and further work will be required
to understand these findings.
Increasedplasma renin activity . Although themeanplasma
renin activities of the two water loads were similar, the
patterns during the water loads were different. In previous
studies(29), and during the control water loadsof this study,
plasma renin activity decreased 15 to 20% during a water
load. However, with nisoldipine plasma renin activity par-
adoxically increased, suggesting that nisoldipine signifi-
cantly alters the response of these patients to a water load.
This is probably the result of a decrease in mean arterial
pressureand secondaryrenin release. These results are con-
sistent with previousacute studiesof calciumentry blockers
such as nifedipine in patients with congestive heart failure
(9,17). Why the plasma renin activity values were lower
before the chronic water load as compared with before the
acute water load remains uncertain, especially considering
the fact that mean arterial pressure was lower at this time.
Increased plasma norepinephrine. Four of the seven
patients who eventually requiredreadmission for worsening
failure had an increase in plasma norepinephrine to values
over 1,000 pg/ml, suggesting a relation between marked
sympathetic activation and clinical deterioration in these
patients. This tendencyof nisoldipine to cause more marked
and sustained increases in plasma norepinephrine is con-
sistent with previousacute studiesof calciumentry blockers
such as nifedipine (5,9, 17)and with chronic studiesof other
neurohumorally inactive vasodilators such as prazosin and
hydralazine (21,29,43) in patients with severe congestive
heart failure.
Decreased plasma aldosterone. The long-term decrease
in plasma aldosterone caused by nisoldipine was probably
due to both the long-term decrease in plasma potassiumseen
in our patientsand to direct inhibitionof aldosterone release
by nisoldipine (44). The inhibitory effect of nisoldipine on
aldosterone release is well illustrated in our study. During
the water load with nisoldipine, plasma aldosterone tended
to decrease despite a significant increase in plasma renin
activity.
Conclusions. Despite having some beneficial hemody-
namic effects, the calcium entry blocker nisoldipine may
worsen the symptomsof patients in congestiveheart failure.
Nisoldipine may worsenheart failure by causing an increase
in neurohumoral stimulation, especially in those patients
with more severe heart failure and more baseline neuro-
humoral stimulation.
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